MFS

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Retrieved on: 
Wednesday, April 3, 2024
Sarcoma, TCON, Patient, SAN, PDP, Safety, UPS, MFS, Therapy, IDMC, Medical imaging

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent Product Development Platform (PDP) to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, today announced the independent data monitoring committee (IDMC), following a review of ongoing safety and efficacy data on April 2, recommended the ENVASARC Phase 2 pivotal trial continue as planned. The ENVASARC Phase 2 pivotal trial completed enrollment in March 2024 with a total of 82 evaluable patients in cohort C of treatment with single agent envafolimab at 600 mg SQ every three weeks and final data are expected in the third quarter of 2024.

Key Points: 
  • The ENVASARC Phase 2 pivotal trial completed enrollment in March 2024 with a total of 82 evaluable patients in cohort C of treatment with single agent envafolimab at 600 mg SQ every three weeks and final data are expected in the third quarter of 2024.
  • The IDMC reviewed interim safety and efficacy data from 73 patients enrolled into cohort C who had the opportunity to complete two on-treatment scans (a minimum of 12 weeks of treatment).
  • The objective response rate (ORR) is currently 11% by investigator review and the confirmed ORR by blinded independent central review (BICR) is currently 5.5% (four patients).
  • Envafolimab has been well tolerated without the development of a single drug-related serious adverse event of grade 3 or higher.

MFS Investment Management Announces Planned Liquidation of MFS Special Value Trust

Retrieved on: 
Tuesday, February 13, 2024
Banking, Asset Management, Professional Services, Finance, MFS Investment Management, MFS, Trustee, Security (finance)

MFS Investment Management® (“MFS®”) announced that, at a meeting held today, the Board of Trustees of MFS® Special Value Trust (the “fund”) (NYSE: MFV), a closed-end management investment company, approved a plan of liquidation and termination for the fund (the "liquidation").

Key Points: 
  • MFS Investment Management® (“MFS®”) announced that, at a meeting held today, the Board of Trustees of MFS® Special Value Trust (the “fund”) (NYSE: MFV), a closed-end management investment company, approved a plan of liquidation and termination for the fund (the "liquidation").
  • The liquidation is currently expected to be completed on or about April 29, 2024.
  • MFS and the Board also considered alternatives, including merging the fund into another investment company and modifying the strategy of the fund.
  • On balance MFS and the Board determined that a liquidation would be in the best interests of the fund and its shareholders.

Monterey Financial Services, LLC: Unparalleled Timeshare Financing Expertise at GNEX 2024 Conference

Retrieved on: 
Friday, February 9, 2024
SAN, GNEX, Conference, MFS, Account executive, Bank

SAN DIEGO, Feb. 9, 2024 /PRNewswire/ -- Monterey Financial, LLC, (MFS) has been a leading player in the Consumer Finance, Loan Servicing Management, and Delinquent Debt Recovery sectors for over thirty years. Known for its innovative approach to solving complex financial receivables challenges faced by entrepreneurs across various industries, MFS is delighted to share that it will be participating as a Bronze sponsor at the highly anticipated GNEX 2024 Conference at the Historic Fontainebleau, Miami Beach, Florida scheduled from February 20-22, 2024. During the event, MFS will showcase its expertise in the vacation industry, offering insightful solutions to meet the unique needs of businesses in this field.

Key Points: 
  • At the GNEX Miami 2024 Conference, MFS will be showcasing innovative new solutions in both timeshare and travel club financing opportunities.
  • Gina Frame, Monterey Financial's esteemed Account Executive, and former GNEX presenter exclaims, "We are honored to attend and exhibit at GNEX Miami 2024.
  • MFS Financial invites everyone to visit their dedicated booth at the GNEX 2024 Conference.
  • Stop by to connect with Monterey Financial, LLC participating and sponsoring in the esteemed GNEX 2024 Conference at the Fontainebleau in Miami Beach, Florida scheduled from February 20-22, 2024.

NDRI Announces Organ Procurement Organization Partnerships and Program Manager for the Somatic Mosaicism across Human Tissues (SMaHT) Network

Retrieved on: 
Wednesday, February 7, 2024
Research, Surgery, Hospitals, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Science, Partnership, AACR, Skin cancer, Mosaic, Hospital, Gift, Maryland School, Genetic variation, Johns Hopkins, Wright State University, ELSI, OPO, MFS, Disease, Tissue, TPC, Bangladesh Technical Education Board, Doctor of Philosophy, University, CPTC, Network, NDRI, Ethics, Pharmaceutical industry

The National Disease Research Interchange (NDRI) is pleased to announce its recovery network and program manager for the Somatic Mosaicism across Human Tissues (SMaHT) Tissue Procurement Center.

Key Points: 
  • The National Disease Research Interchange (NDRI) is pleased to announce its recovery network and program manager for the Somatic Mosaicism across Human Tissues (SMaHT) Tissue Procurement Center.
  • The SMaHT Network is an NIH Common Fund initiative that will provide the first comprehensive public resource for analyzing genetic variation due to somatic mosaicism in human tissues from all developmental layers in the human body.
  • NDRI, in collaboration with the University of Maryland School of Medicine and Johns Hopkins All Children’s Hospital, serve as the Tissue Procurement Center (TPC) for the SMaHT Network.
  • NDRI’s Organ Procurement Organization (OPO) partnerships for the SMaHT Network will include the Gift of Life Donor Program (Philadelphia, PA), ConnectLife (Williamsville, NY), and LifeGift (Houston, TX).

Elevate Quantum Adds Four New Members to Board of Directors

Retrieved on: 
Thursday, February 1, 2024
Level 3, Rocky Mountain PBS, Metropolitan Fiber Systems, Transport, University of Colorado Boulder, Commerce, Economic development, Former, Public policy, State, ICG, Metropolitan, Built environment, MFS, University, Small business, International trade, Quantum, Workforce, Zayo Group, Front Range Community College, Research, Office, Executive, National Council, Innovation, Museum, Management

DENVER, Feb. 1, 2024 /PRNewswire-PRWeb/ -- Industry leaders join forces to ensure that Colorado, New Mexico, and Wyoming remain the premier quantum tech hub in America.

Key Points: 
  • Elevate Quantum, a designated TechHub by the US Department of Commerce Economic Development Administration, today announced the appointment of four new members to its Board of Directors.
  • "With the guidance of our new Board of Directors, Elevate Quantum is well-equipped to strengthen Colorado's position as the premier quantum tech hub in America," said Corban Tillemann-Dick, Chair of Elevate Quantum's Board of Directors and Founder and CEO of Maybell Quantum Industries.
  • Elevate Quantum , a designated TechHub by the US Department of Commerce Economic Development Administration, today announced the appointment of four new members to its Board of Directors.
  • "With the guidance of our new Board of Directors, Elevate Quantum is well-equipped to strengthen Colorado's position as the premier quantum tech hub in America," said Corban Tillemann-Dick, Chair of Elevate Quantum's Board of Directors and Founder and CEO of Maybell Quantum Industries.

XTANDI® (enzalutamide) Receives Health Canada Approval as the First and Only Treatment for High-Risk Patients with Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC)

Retrieved on: 
Tuesday, January 30, 2024
Orbis, Patient, Prostate cancer, BCR, Therapy, Professor, MFS, Radiation, University, Cancer, Recurrence, Metastasis, Acquisition, Université de Montréal, ADT, New Drug Application, Gonadotropin-releasing hormone, Health Canada, Prostate, Diagnosis, Physician, Pharmaceutical industry

MARKHAM, ON, Jan. 30, 2024 /CNW/ - Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting.

Key Points: 
  • MARKHAM, ON, Jan. 30, 2024 /CNW/ - Today, Astellas Pharma Canada, Inc. announced that Health Canada has approved a supplemental New Drug Application for XTANDI® (enzalutamide) in a new prostate cancer treatment setting.
  • "I welcome the approval of XTANDI as a promising earlier treatment option for eligible patients.
  • This marks a significant step forward in addressing unmet needs for prostate cancer treatment."
  • With our recent acquisition of Propella Therapeutics, Inc., we strive to achieve even more in the investigation of targeted prostate cancer treatments for patients of the future."

eGenesis and OrganOx Announce Successful Use of a Genetically Engineered Porcine Liver with a Human Donor

Retrieved on: 
Thursday, January 18, 2024
Other Health, Other Science, Pharmaceutical, Research, Software, Medical Devices, Hospitals, Genetics, Data Management, Science, Technology, Veterinary, Clinical Trials, General Health, FDA, Biotechnology, Surgery, Health, Mortality, Hope, Family, Patient, Coagulation, Liver failure, Multimedia, ELC, MFS, Pelvic floor dysfunction, Gift, Gene, University, Drug discovery, Risk, Perfusion, Transgene, IND, Food, Pressure, Liver, Inflammation, Genome, Organization, CPTC, Bile, Cell, Trial of the century, Dietary supplement

The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.

Key Points: 
  • The perfusion was performed using the eGenesis liver, EGEN-5784, connected to the OrganOx extracorporeal liver cross-circulation (ELC) device to enable circulation of the donor’s blood through the porcine liver.
  • The efficacy of existing liver support options is limited, and patients in liver failure face a high risk of mortality.
  • For some patients, utilizing a human-compatible, genetically engineered porcine whole liver to support the function of a patient’s decompensated liver may provide time for the recovery of the patient’s native liver or time to obtain a liver transplant.
  • The genetically engineered porcine liver used in this study carried the same genetics as the porcine kidneys used in the landmark preclinical study recently published in Nature .

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.

Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

Retrieved on: 
Thursday, January 25, 2024
Patient, Medication, Emerging market, GSSA, Action Replay, Microsatellite, MSI-H, Chinese, MFS, CIS, Cholangiocarcinoma, UPS, Cancer, License, PD-L1, STS, Lung cancer, Neoplasm, Prevalence, Myxofibrosarcoma, National Medical Products Administration, LTD, NMPA

Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.

Key Points: 
  • Jiangsu Alphamab will be responsible of manufacturing KN035 within and outside the Territory.
  • 3D Medicines retains the right to develop and commercialize Envafolimab for any purpose outside the Territory.
  • Under the terms of the agreement, GSSA will receive from Jiangsu Alphamab and 3D Medicines, an exclusive license to develop, register, commercialize, Envafolimab for the oncology indication in the Territory.
  • The Licensors' respective entitlement to the payments (including the upfront payment, milestone payment and the royalty fees) under the License Agreement are subject to the agreements between 3D Medicines and Jiangsu Alphamab.